

# Silvia Crescioli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3309924/publications.pdf>

Version: 2024-02-01

42  
papers

1,623  
citations

361413

20  
h-index

330143

37  
g-index

42  
all docs

42  
docs citations

42  
times ranked

2391  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibodies to watch in 2022. <i>MAbs</i> , 2022, 14, 2014296.	5.2	239
2	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 453.	4.8	177
3	Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). <i>Oncolmunology</i> , 2018, 7, e1395127.	4.6	117
4	Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types. <i>Frontiers in Immunology</i> , 2017, 8, 1911.	4.8	87
5	IgG4 Characteristics and Functions in Cancer Immunity. <i>Current Allergy and Asthma Reports</i> , 2016, 16, 7.	5.3	76
6	BRAF inhibitors: resistance and the promise of combination treatments for melanoma. <i>Oncotarget</i> , 2017, 8, 78174-78192.	1.8	75
7	Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. <i>European Journal of Immunology</i> , 2021, 51, 544-556.	2.9	71
8	Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5098-5111.	7.0	65
9	Anti-Folate Receptor-Î± IgE but not IgG Recruits Macrophages to Attack Tumors via TNF-Î±/MCP-1 Signaling. <i>Cancer Research</i> , 2017, 77, 1127-1141.	0.9	58
10	hERG1 Channels Regulate VEGF-A Secretion in Human Gastric Cancer: Clinicopathological Correlations and Therapeutical Implications. <i>Clinical Cancer Research</i> , 2014, 20, 1502-1512.	7.0	54
11	AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 328-340.	5.7	54
12	IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin. <i>Scientific Reports</i> , 2016, 6, 29736.	3.3	52
13	B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment. <i>Oncolmunology</i> , 2017, 6, e1294296.	4.6	51
14	The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression. <i>Science Signaling</i> , 2017, 10, .	3.6	49
15	IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states. <i>EBioMedicine</i> , 2019, 43, 67-81.	6.1	49
16	Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 4290-4304.	0.9	40
17	B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies. <i>Frontiers in Immunology</i> , 2020, 11, 622442.	4.8	39
18	An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2328-2341.	5.7	24

#	ARTICLE	IF	CITATIONS
19	Utilizing Immunocytokines for Cancer Therapy. <i>Antibodies</i> , 2021, 10, 10.	2.5	24
20	A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma. <i>Cancers</i> , 2020, 12, 1029.	3.7	22
21	Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1519-1523.e9.	2.9	19
22	In Planta Glycan Engineering and Functional Activities of IgE Antibodies. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 242.	4.1	19
23	Generation and characterization of novel recombinant anti-HERG1 scFv antibodies for cancer molecular imaging. <i>Oncotarget</i> , 2018, 9, 34972-34989.	1.8	19
24	Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields. <i>Frontiers in Immunology</i> , 2017, 8, 1112.	4.8	17
25	Recombinant plant-derived human IgE glycoproteomics. <i>Journal of Proteomics</i> , 2017, 161, 81-87.	2.4	16
26	Harnessing the hERG1/ $\alpha$ 21 Integrin Complex via a Novel Bispecific Single-chain Antibody: An Effective Strategy against Solid Cancers. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1338-1349.	4.1	16
27	Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments. <i>Cancers</i> , 2021, 13, 4460.	3.7	15
28	Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells. <i>Frontiers in Immunology</i> , 2018, 9, 493.	4.8	14
29	AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1985-1989.	5.7	14
30	<i>In vivo</i> safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model. <i>MAbs</i> , 2020, 12, 1685349.	5.2	11
31	Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs). <i>Scientific Reports</i> , 2020, 10, 8869.	3.3	11
32	Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. , 2021, 9, e002140.		10
33	AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2594-2617.	5.7	5
34	Innate stimulation of B cells <i>ex vivo</i> enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients. <i>Clinical and Experimental Immunology</i> , 2022, 207, 84-94.	2.6	4
35	VEGF-A clinical significance in gastric cancers: Immunohistochemical analysis of a wide Italian cohort. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1291-1298.	1.0	3
36	Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG1 and IgG4 against the Major Birch Pollen Allergen Bet v 1. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5693.	4.1	3

#	ARTICLE	IF	CITATIONS
37	<i>In vivo</i> trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart. <i>Oncolmmunology</i> , 2021, 10, 1966970.	4.6	2
38	Abstract LB-001: Development and evaluation of T-Zap: a novel antibody-drug conjugate for the treatment of Her2 positive breast cancer. , 2018, , .		1
39	Special Issue “Antibody Engineering for Cancer Immunotherapy”. <i>Antibodies</i> , 2022, 11, 29.	2.5	1
40	Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples. , 2021, , 329-350.		0
41	Abstract 1324: A translational platform to design antibodies targeting triple negative breast cancer-specific antigens for cancer immunotherapy. , 2015, , .		0
42	Abstract A116: IgG antibody switching and clonal expansion in melanoma and normal skin microenvironments. , 2016, , .		0